Tempest Therapeutics (NASDAQ:TPST) Stock Rating Reaffirmed by HC Wainwright

Tempest Therapeutics (NASDAQ:TPST)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a report released on Thursday, Benzinga reports. They presently have a $47.00 target price on the stock.

Several other equities analysts have also recently weighed in on TPST. Scotiabank started coverage on Tempest Therapeutics in a research note on Thursday, March 14th. They set a “sector outperform” rating and a $13.00 price objective on the stock. William Blair restated an “outperform” rating on shares of Tempest Therapeutics in a research note on Wednesday, March 20th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $20.75.

Tempest Therapeutics Price Performance

Shares of TPST opened at $2.03 on Thursday. Tempest Therapeutics has a 12-month low of $0.17 and a 12-month high of $9.77. The business’s fifty day moving average is $3.24 and its 200 day moving average is $3.69. The company has a quick ratio of 3.13, a current ratio of 3.13 and a debt-to-equity ratio of 0.20. The stock has a market cap of $45.11 million, a P/E ratio of -1.18 and a beta of -1.78.

Tempest Therapeutics (NASDAQ:TPST) last issued its quarterly earnings data on Thursday, May 9th. The company reported ($0.36) earnings per share for the quarter, beating the consensus estimate of ($0.44) by $0.08. Sell-side analysts anticipate that Tempest Therapeutics will post -1.58 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Tempest Therapeutics

An institutional investor recently bought a new position in Tempest Therapeutics stock. MayTech Global Investments LLC bought a new position in shares of Tempest Therapeutics, Inc. (NASDAQ:TPST) during the fourth quarter, according to its most recent filing with the SEC. The fund bought 10,000 shares of the company’s stock, valued at approximately $44,000. Tempest Therapeutics accounts for 0.0% of MayTech Global Investments LLC’s investment portfolio, making the stock its 29th largest holding. MayTech Global Investments LLC owned about 0.05% of Tempest Therapeutics at the end of the most recent reporting period. 22.52% of the stock is currently owned by institutional investors.

Tempest Therapeutics Company Profile

Tempest Therapeutics, Inc, a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors.